CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-1.82 Insider Own0.40% Shs Outstand144.62M Perf Week-14.24%
Market Cap44.23M Forward P/E- EPS next Y-0.79 Insider Trans-7.52% Shs Float142.87M Perf Month-68.99%
Income-251.90M PEG- EPS next Q-0.31 Inst Own25.90% Short Float / Ratio19.61% / 6.87 Perf Quarter-73.74%
Sales133.00M P/S0.33 EPS this Y47.70% Inst Trans-14.77% Short Interest28.02M Perf Half Y-56.60%
Book/sh-2.89 P/B- EPS next Y51.60% ROA-60.60% Target Price- Perf Year-89.44%
Cash/sh0.38 P/C0.76 EPS next 5Y- ROE73.70% 52W Range0.23 - 3.32 Perf YTD-89.24%
Dividend- P/FCF- EPS past 5Y24.10% ROI-67.70% 52W High-92.44% Beta0.21
Dividend %- Quick Ratio0.10 Sales past 5Y353.00% Gross Margin72.20% 52W Low10.62% ATR0.07
Employees413 Current Ratio0.10 Sales Q/Q-19.00% Oper. Margin- RSI (14)26.30 Volatility11.71% 15.23%
OptionableYes Debt/Eq- EPS Q/Q30.40% Profit Margin- Rel Volume1.18 Prev Close0.29
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume4.08M Price0.25
Recom3.50 SMA20-36.54% SMA50-69.21% SMA200-81.74% Volume2,924,127 Change-13.86%
May-06-22Downgrade H.C. Wainwright Buy → Neutral
May-18-20Reiterated H.C. Wainwright Buy $29 → $33
Apr-27-20Downgrade SVB Leerink Mkt Perform → Underperform $5
Apr-09-20Downgrade BofA/Merrill Neutral → Underperform $6
Jan-08-20Reiterated H.C. Wainwright Buy $36 → $27
Nov-19-19Downgrade Evercore ISI Outperform → In-line $8
Sep-24-19Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Show Previous Ratings
Nov-25-22 12:34PM
Nov-21-22 09:35AM
Nov-18-22 01:11PM
Nov-11-22 05:33AM
Nov-10-22 10:46AM
12:37PM Loading…
Nov-09-22 12:37PM
11:11AM
09:55AM
08:44AM
Oct-27-22 05:05PM
10:03AM
Oct-26-22 10:02AM
Oct-17-22 03:45AM
Oct-03-22 01:35PM
07:00AM
11:29AM Loading…
Sep-21-22 11:29AM
08:00AM
Sep-14-22 01:09PM
Sep-13-22 08:00AM
Sep-12-22 07:09PM
09:11AM
Sep-11-22 10:30AM
Sep-07-22 11:30AM
Aug-14-22 08:19AM
Aug-08-22 01:37PM
12:42PM
09:15AM
08:00AM
Aug-02-22 10:00AM
Aug-01-22 10:01AM
08:30AM Loading…
08:30AM
Jul-20-22 06:06PM
Jul-19-22 03:43PM
Jul-15-22 09:53AM
Jul-08-22 03:55PM
11:36AM
Jul-07-22 04:33PM
12:27PM
07:45AM
Jun-21-22 12:18PM
Jun-16-22 04:20PM
Jun-15-22 07:49AM
Jun-14-22 02:00PM
Jun-10-22 10:23AM
Jun-06-22 08:00AM
Jun-03-22 11:31AM
Jun-01-22 08:19AM
May-16-22 08:30AM
May-09-22 11:05AM
May-06-22 01:23PM
07:12AM
May-05-22 10:22AM
08:00AM
May-04-22 02:21PM
09:15AM
08:00AM
May-03-22 08:35AM
May-02-22 12:21PM
10:01AM
Apr-28-22 08:00AM
Apr-27-22 03:03PM
Apr-20-22 08:00AM
Apr-18-22 04:51PM
Apr-08-22 02:54PM
08:00AM
Apr-04-22 03:11PM
Mar-31-22 05:06PM
04:41PM
09:22AM
08:01AM
06:00AM
Mar-25-22 11:30AM
Mar-16-22 08:00AM
Feb-26-22 06:34AM
Feb-25-22 08:00AM
Feb-24-22 02:49PM
Feb-23-22 08:05AM
Feb-10-22 04:05PM
Jan-19-22 10:15AM
Jan-10-22 08:00AM
Jan-03-22 10:07AM
Dec-09-21 08:00AM
Dec-03-21 11:31AM
Nov-04-21 06:46AM
Nov-03-21 09:15AM
08:00AM
07:48AM
Oct-27-21 03:03PM
Oct-20-21 08:00AM
Oct-19-21 08:00AM
Oct-15-21 09:15AM
Oct-07-21 09:00AM
Sep-29-21 10:00AM
Sep-20-21 08:00AM
Sep-03-21 11:31AM
Aug-27-21 11:37AM
Aug-24-21 02:00AM
Aug-16-21 04:21PM
Aug-05-21 10:57AM
02:34AM
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rolfe LindseySee RemarksNov 02Sale0.984,2614,188111,419Nov 03 04:15 PM
MUEHL DANIEL WSee RemarksNov 02Sale0.984,5794,501102,271Nov 03 04:15 PM
Harding Thomas C.See RemarksNov 02Sale0.9863623,801Nov 03 04:15 PM
Harding Thomas C.See RemarksNov 02Sale0.981,7031,67418,590Nov 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksNov 02Sale0.983,6813,618290,993Nov 03 04:15 PM
Gross Paul EdwardSee RemarksNov 02Sale0.984,7304,64995,840Nov 03 04:15 PM
Harding Thomas C.See RemarksOct 03Sale1.29683,683Oct 04 04:15 PM
MUEHL DANIEL WSee RemarksSep 02Sale1.202,2342,68199,161Sep 06 04:15 PM
IVERS-READ GILLIAN CSee RemarksSep 02Sale1.202,2342,681288,919Sep 06 04:15 PM
Harding Thomas C.See RemarksSep 02Sale1.201722063,674Sep 06 04:15 PM
Harding Thomas C.See RemarksSep 02Sale1.201,4441,73317,816Sep 06 04:15 PM
Gross Paul EdwardSee RemarksSep 02Sale1.202,3082,77092,812Sep 06 04:15 PM
Rolfe LindseySee RemarksSep 02Sale1.202,5453,054109,578Sep 06 04:15 PM
Gross Paul EdwardSee RemarksAug 02Sale1.464,8077,02487,601Aug 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksAug 02Sale1.463,8025,555283,565Aug 03 04:15 PM
Rolfe LindseySee RemarksAug 02Sale1.464,3306,326104,826Aug 03 04:15 PM
MUEHL DANIEL WSee RemarksAug 02Sale1.464,6546,79993,807Aug 03 04:16 PM
Harding Thomas C.See RemarksAug 02Sale1.46771123,338Aug 03 04:15 PM
Harding Thomas C.See RemarksAug 02Sale1.461,7322,53015,481Aug 03 04:15 PM
Harding Thomas C.See RemarksJul 05Sale2.717193,234Jul 06 04:15 PM
Rolfe LindseySee RemarksJun 02Sale0.642,6501,703103,016Jun 03 04:15 PM
Harding Thomas C.See RemarksJun 02Sale0.642181403,225Jun 03 04:15 PM
Harding Thomas C.See RemarksJun 02Sale0.641,50496614,720Jun 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksJun 02Sale0.642,3271,495281,518Jun 03 04:15 PM
Gross Paul EdwardSee RemarksJun 02Sale0.642,4031,54484,615Jun 03 04:15 PM
MUEHL DANIEL WSee RemarksJun 02Sale0.642,3271,49590,737Jun 03 04:15 PM
MUEHL DANIEL WSee RemarksMay 02Sale1.974,5709,00285,439May 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksMay 02Sale1.973,7337,353276,220May 03 04:15 PM
Gross Paul EdwardSee RemarksMay 02Sale1.974,5709,00279,393May 03 04:15 PM
Rolfe LindseySee RemarksMay 02Sale1.974,2528,37698,327May 03 04:15 PM
Harding Thomas C.See RemarksMay 02Sale1.97761502,936May 03 04:15 PM
Harding Thomas C.See RemarksMay 02Sale1.971,7003,34912,429May 03 04:15 PM
Harding Thomas C.See RemarksApr 04Sale2.667192,831Apr 05 04:16 PM
Gross Paul EdwardSee RemarksMar 02Sale1.8710,70619,97766,444Mar 03 04:15 PM
Rolfe LindseySee RemarksMar 02Sale1.8710,94520,42386,817Mar 03 04:15 PM
MUEHL DANIEL WSee RemarksMar 02Sale1.8710,70619,97772,490Mar 03 04:16 PM
Harding Thomas C.See RemarksMar 02Sale1.878801,6421,662Mar 03 04:15 PM
Harding Thomas C.See RemarksMar 02Sale1.876,94612,9616,850Mar 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksMar 02Sale1.8710,77020,097264,308Mar 03 04:15 PM
Rolfe LindseySee RemarksFeb 02Sale1.944,5148,75684,357Feb 03 04:17 PM
MUEHL DANIEL WSee RemarksFeb 02Sale1.945,43610,54470,045Feb 03 04:15 PM
Harding Thomas C.See RemarksFeb 02Sale1.94811571,652Feb 03 04:15 PM
Harding Thomas C.See RemarksFeb 02Sale1.942,0373,9516,015Feb 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksFeb 02Sale1.944,4428,616261,802Feb 03 04:16 PM
Gross Paul EdwardSee RemarksFeb 02Sale1.945,43610,54463,999Feb 03 04:15 PM
Harding Thomas C.See RemarksJan 03Sale2.757191,551Jan 04 04:15 PM